Lisata Therapeutics, Inc. develops investigational therapies for advanced solid tumors and other serious diseases. Its principal product candidate, certepetide, is a proprietary iRGD cyclic peptide designed to activate an uptake pathway that can improve tumor targeting and penetration by co-administered or tethered anti-cancer agents.
Recurring Lisata news covers clinical and preclinical data involving certepetide, collaborations and license agreements tied to antibody-drug conjugates and other delivery technologies, development-rights changes for regional markets, financial results, business updates, and corporate matters affecting governance or capital structure.
Lisata Therapeutics (Nasdaq: LSTA) appointed Jeffrey Farrow to its Board of Directors as a Class III director, effective October 13, 2026. Farrow fills a newly created seat, expanding the Board from seven to eight members, and will serve on the Audit Committee. The Board determined that he is independent under Nasdaq listing rules.
Farrow currently serves as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, roles he has held since April 2023. He also serves on the boards of Clover Biopharmaceuticals and Achieve Life Sciences.
Lisata Therapeutics (Nasdaq: LSTA) has received a U.S. method-of-use patent for certepetide to treat pancreatic cancer and other solid tumors.
U.S. Patent No. 12,751,991 expires in May 2041 and expands the drug’s intellectual property protection. It covers administering certepetide, the company’s proprietary cyclic peptide, with at least one anti-cancer agent or therapy to treat, inhibit or reduce tumor volume. Covered cancers include metastatic, refractory and drug-resistant cancers—those that have spread, resist treatment or resist drugs.
Lisata Therapeutics (LSTA) subsidiary Marea Therapeutics has dosed the first patient in its Phase 2 trial of MAR002 for acromegaly. MAR002 is an investigational antibody that blocks the growth hormone receptor. The study plans to enroll approximately 72 participants across three MAR002 dose arms, after an initial 900 mg loading dose, compared with placebo. Its primary endpoint is reduction in insulin-like growth factor-1 (IGF-1) following 10 weeks of treatment. Eligible participants completing that period may enter an open-label extension trial, where treatment is known to participants and researchers.
Phase 1 results presented in June 2026 showed sustained IGF-1 suppression. Marea said the drug's pharmacokinetic properties—how it moves through the body—may enable dosing as infrequently as once every two weeks, versus daily subcutaneous injections required by the current standard of care.
Marea Therapeutics, a Lisata Therapeutics (LSTA) subsidiary, announced a November 9, 2026 presentation of Phase 2b MAR001 data.
The late-breaking session at the American Heart Association Scientific Sessions in Chicago is scheduled for 8:00 a.m. CT. The TYDAL study evaluates MAR001, an antibody targeting ANGPTL4, in adults with elevated triglycerides and remnant cholesterol concentrations.
Lisata Therapeutics (LSTA) announced the acquisition of clinical‑stage biotech Marea Therapeutics and a concurrent private placement expected to raise approximately $225 million in gross proceeds. The combined company will focus on developing first‑in‑class, next‑generation medicines for cardioendocrine diseases, led by Marea’s late‑stage clinical candidates MAR001/005 for severe hypertriglyceridemia (sHTG) and MAR002 for acromegaly.
The private placement consists of Series C non‑voting convertible preferred stock sold to a syndicate of leading life sciences and institutional investors, with funding projected to support operations into 2028. Lisata plans to use the net proceeds primarily to complete an ongoing Phase 2b trial of MAR001/005 in sHTG and a Phase 2 trial of MAR002 in acromegaly, both expected to deliver topline data in the fourth quarter of 2027, with remaining funds for general corporate purposes.
Summary not available.
Lisata Therapeutics (Nasdaq:LSTA) announced that Kuva Labs subsidiary Kuva Acquisition has commenced a tender offer to acquire all Lisata shares. Stockholders would receive $4.00 in cash plus a non-tradeable CVR for up to $3.00 per share, subject to clinical and regulatory milestones.
The offer, unanimously recommended by Lisata’s board, expires July 10, 2026 and is expected to close in Q3 2026, subject to sufficient tenders and customary conditions. Post-closing, Lisata will be merged into Kuva, delisted from Nasdaq, and deregistered as a reporting company.
Lisata Therapeutics (Nasdaq: LSTA) agreed to be acquired by Kuva Labs for $5.00 per share in cash at closing plus one contingent value right (CVR) per share that may pay an additional $1.00 if an NDA or similar regulatory filing for certepetide is filed or accepted within seven years. The Lisata board unanimously approved and recommends tendering; the tender offer is expected to close in Q2 2026, will not include a financing condition, and will result in Lisata common stock being delisted and deregistered post-closing.
Lisata Therapeutics (Nasdaq: LSTA) announced a mutual termination of its February 2021 Exclusive License and Collaboration Agreement with Qilu Pharmaceutical, causing all licenses and rights for certepetide in the Greater China region to revert to Lisata.
The original agreement had granted Qilu exclusive development and commercialization rights in Mainland China, Hong Kong, Macau, and Taiwan; those rights now return to Lisata following the termination. Qilu remains responsible for completing and winding down an ongoing Phase 2 clinical study (NCT06261359) of certepetide with chemotherapy in metastatic pancreatic ductal adenocarcinoma. Lisata will negotiate with Qilu about potential licensing of relevant trial data.
Lisata Therapeutics (Nasdaq: LSTA) entered a binding term sheet to be acquired by Kuva Labs in an all-cash tender offer of $4.00 per share. Stockholders will also receive two non-tradeable contingent value rights (CVRs) worth $1.00 each payable upon (1) reversion of certain Greater China rights and (2) Kuva filing an NDA or similar registration for certepetide.
The boards of both companies approved the term sheet unanimously and expect a definitive purchase agreement prior to February 27, 2026. The cash offer is an approximate 85% premium to the most recent close and, including both CVRs, an approximate 180% premium.